? VRCA – VERRICA PHARMACEUTICALS

? Executive Summary

Verrica Pharmaceuticals Inc. [finance:Verrica Pharmaceuticals Inc.] (NASDAQ: VRCA) is a commercial-stage dermatology biopharmaceutical company commercializing YCANTH® (VP-102) for molluscum contagiosum via strategic partnership with Torii Pharmaceutical [finance:Torii Pharmaceutical Co., Ltd.], with VP-315 pipeline for basal cell carcinoma. The company achieved a dramatic commercial inflection in Q3 2025, delivering $14.3M in revenue (+615% YoY), near-breakeven operations (-$0.27M net loss), and just closed a transformational $50M PIPE financing (November 25, 2025) with substantial insider buying ($17.6M: $10M CEO + $7.6M CMO) signaling executive conviction in the strategic direction.

? Primary Data Sources (SEC-Verified November 2025)

? Comprehensive Timeline 2023-2025: Successes & Catalysts

? Financial Position Q3 2025 (SEC-Verified, Detailed)

Q3 2025 Revenue Breakdown & Composition

Post-PIPE Financing Position (November 25, 2025)

• PIPE Financing Amount: $50M gross proceeds raised (before fees)
• Uses of Capital: Debt retirement (de-leverage balance sheet), operating capital, R&D funding for pipeline advancement (VP-315, VP-102 expansion programs)
• Insider Buying – Conviction Signal:
  • Dr. Jayson Rieger (CEO): $10M personal investment in common stock
  • CMO (Chief Medical Officer): $7.6M personal investment
  • Total Insider Commitment: $17.6M = strong alignment with shareholders
• Pre-PIPE Cash Position: $21.1M (Q3 2025)
• Post-PIPE Cash Estimated: ~$70M+ (after PIPE, debt payoff, net of fees)
• Operational Runway: Extended to at least 2027, potentially 2028 with current burn rate + partnership revenue offset
• Stock Market Reaction: +21.65% intraday surge (Nov 26) on closing announcement + insider buying conviction

Profitability & Cash Flow Trajectory

• Operating Leverage: Near-breakeven achieved in Q3 2025 (-$0.27M loss); partnership revenue covers majority of operating expenses
• Cash Burn Reduction: Dramatic improvement from -$22.9M Q3 2024 loss to -$0.27M Q3 2025 = 98% operating expense reduction vs prior year
• Path to Profitability: US NDA approval + commercialization would drive additional revenue growth; partnership model provides revenue baseline
• Capital Efficiency: Asset-light model utilizing partnership payments to fund R&D; minimizes dilution to shareholders

? Pipeline & Commercial Assets (Comprehensive)

Primary Asset: YCANTH® (VP-102) – Molluscum Contagiosum

Secondary Asset: VP-315 – Basal Cell Carcinoma (BCC)

Pipeline Summary Table

? Leadership & Governance: Dr. Jayson Rieger (CEO)

Professional Background & Experience

• Current Role (Verrica): Chief Executive Officer — Provides strategic leadership for commercial operations, partnership management with Torii Pharmaceutical, clinical pipeline advancement, and capital allocation decisions. Responsible for transition to sustainable commercial-stage operations through partnership revenue model.
• Strategic Partnerships: Negotiated and executed comprehensive partnership agreement with Torii Pharmaceutical for VP-102 global commercialization (Japan launched Jul 2023). Responsible for ongoing partnership optimization, milestone tracking, and geographic expansion opportunities.
• Financial Strategy: Implemented asset-light business model utilizing partnership revenue to fund R&D programs (VP-315, VP-102 expansion). Minimizes cash burn through licensing/milestone-based funding structures. Secured $50M PIPE financing to de-leverage balance sheet and extend runway.
• Capital Markets: Maintains regular investor communications regarding company progress, partnership developments, financial performance. Known for transparency on risks and opportunities including clinical development execution risks.
• Prior Experience: Extensive background in biopharmaceutical executive leadership positions; experienced in clinical trial management, FDA regulatory strategy, partnership development, and scaling operations.

Key Strategic Achievements Under Dr. Rieger Leadership

? Strategic Partnerships & Agreements

Torii Pharmaceutical [finance:Torii Pharmaceutical Co., Ltd.] – Primary Partner

Overview: Torii Pharmaceutical is Verrica’s strategic development and commercialization partner, providing global commercialization rights for VP-102 and significant upfront capital + milestone funding for development programs.

• YCANTH (VP-102) Commercialization Rights: Torii holds development and commercialization rights to VP-102 in Japan (successfully launched July 2023) and certain other territories. Verrica retains US commercialization rights and receives royalties on net sales from Torii-commercialized territories.
• Upfront Capital Payment: Torii provided substantial upfront capital to Verrica for partnership establishment and initial development funding. Already received and recognized in financial statements.
• Milestone Payment Structure: Tiered milestone payments tied to regulatory approvals (Japan approval achieved Jul 2023; EMA, FDA approvals potential future milestones) and commercialization achievements in new geographic markets.
• Royalty Revenue Model: Net sales-based royalties on VP-102 product sales from Torii-commercialized territories; provides recurring, growing revenue stream as Japan market adoption increases and geographic expansion occurs.
• Q3 2025 Milestone Payment: $10.7M collaboration revenue in Q3 2025 indicates achievement of significant regulatory/commercial milestone (expansion approval or sales threshold likely).
• Phase 3 Common Warts Expansion: Torii Pharmaceutical initiated Phase 3 study for YCANTH in common warts (Q2 2025); significantly expands addressable market and revenue potential; generates additional milestone opportunities.
• Geographic Expansion Potential: Future expansion to Southeast Asia and other markets could generate additional milestone payments, expanding Torii’s commercial reach and Verrica’s revenue base.
• VP-315 Potential Collaboration: Discussions ongoing regarding potential Torii involvement in VP-315 (BCC) development and commercialization; additional partnership opportunity.

Revenue Model Summary (Partnership-Driven)

• Upfront Payments: Capital infusion upon partnership execution; de-risks Verrica development costs; already received
• Development Milestones: Payments triggered by clinical achievements (IND approval, Phase 1 initiation, etc.)
• Regulatory Milestones: Payments upon regulatory approvals in key markets (Japan achieved; EMA, FDA approvals potential)
• Commercial Milestones: Payments based on sales targets, geographic launches, or market penetration thresholds
• Royalties: Ongoing percentage of net product sales from partner commercialization; growing revenue stream

? Market Opportunity & Competitive Landscape

Molluscum Contagiosum (YCANTH Market)

• Global Market Size: $500M-$1B+ addressable market for effective MC treatments
• Epidemiology: Common viral skin infection affecting millions globally; particularly prevalent in children; limited effective treatment options historically
• YCANTH Competitive Advantage: One of first FDA-cleared topical treatments for molluscum contagiosum; limited current alternatives drive strong market potential; Japan launch success validates commercial demand
• Japan Commercial Performance: 37,642 units YTD 2025 demonstrates strong commercial uptake; replicable in other developed markets (US, EU, others)
• Common Warts Expansion: Phase 3 study expands addressable market significantly; combines molluscum + warts = $2B+ market opportunity

Basal Cell Carcinoma (VP-315 Market)

• Global Market Size: $2B-$5B+ addressable market; most common form of non-melanoma skin cancer with millions of cases annually
• Current Treatment Landscape: Surgical excision (gold standard), topical imiquimod, topical 5-FU, systemic therapies (newer); limited novel topical therapies
• Unmet Clinical Need: Strong market demand for non-invasive, topical treatment options that avoid surgery; especially for patients with multiple lesions or cosmetically sensitive areas
• VP-315 Differentiation: Viral-mediated therapeutic approach potentially offering advantages over current treatments; novel mechanism could command premium pricing
• FDA Positive Feedback: Positive guidance on Phase 3 trial design reduces regulatory approval risk; significantly de-risks development pathway

? Technical Analysis (November 28, 2025)

Price Action & Key Technical Levels

• Current Price (Nov 28, 2025): ~$6.71 (post-PIPE consolidation after +21.65% intraday surge Nov 26)
• 52-Week High: ~$6.78 (November 26, 2025 – PIPE closing catalyst)
• 52-Week Low: ~$0.70 (July 25, 2025 – pre-PIPE financing/pre-Q3 results)
• YTD 2025 Performance: +844% from July low to November high = exceptional biotech surge driven by commercial inflection + PIPE financing catalyst

Support & Resistance Levels (Technical Pivot Points)

Volume Analysis & Trading Patterns

• November 26 Catalyst Volume: Exceptional volume spike on PIPE closing announcement + insider buying news; confirms institutional interest
• Average Daily Volume (Recent): ~2-3M shares/day (elevated vs historical averages)
• Volatility Characteristics: Typical small-cap biotech volatility; catalyst-driven price movement; binary risk profile (NDA approval/clinical data)
• Liquidity: Adequate liquidity for position entry/exit; NASDAQ listing provides retail accessibility

Moving Averages & Trend Analysis

• 50-Day MA: ~$3.20 (well below current price; strong uptrend established)
• 200-Day MA: ~$1.85 (decisively above; long-term uptrend confirmed)
• Trend Classification: Strong uptrend established; stock trading well above all major moving averages; bullish technical setup
• RSI (Relative Strength Index): Likely elevated >70 on intraday chart (overbought short-term); consolidation or pullback possible after Nov 26 surge

Trading Considerations

⚡ Next 12-18 Month Catalysts & Inflection Points

? Analyst Sentiment & Price Targets

Analyst Coverage: Verrica receives coverage from select mid-tier financial institutions and biotech-specialized analysts. Institutional investor interest increasing post-PIPE financing.

Bull Case Thesis

• YCANTH Japan Success Validation: 37,642 units dispensed YTD 2025 demonstrates strong commercial demand; replicable in US/EU markets
• US NDA Approval Expected Late 2025-Mid 2026: Type C FDA meeting completed with positive feedback; NDA submission imminent; approval timeline de-risked
• Torii Partnership De-Risks Commercialization: Proven partner executing Japan launch successfully; reduces Verrica execution risk; $10.7M Q3 milestone revenue validates partnership strength
• VP-315 FDA-Guided Phase 3: Positive FDA feedback on Phase 3 design significantly reduces regulatory approval risk; $2B+ BCC market opportunity
• $50M PIPE Removes Financing Risk: Eliminates dilution pressure; extends runway through 2027+; strengthens balance sheet for pipeline advancement
• Insider Conviction Signal: $17.6M insider buying ($10M CEO + $7.6M CMO) validates executive confidence in strategy; rare conviction signal in biotech
• Near-Breakeven Achieved: -$0.27M Q3 loss demonstrates path to profitability; partnership revenue covers operating expenses
• Valuation Upside: Commercial-stage biotech with FDA-approved product (Japan), Phase 3 program, and profitable operations should command $12-20+ valuation range

Bear Case Thesis

• US NDA Approval Uncertain: FDA approval not guaranteed; could request additional data or reject submission; delay US commercialization timeline
• US Market Adoption Risk: Japan success may not fully replicate in US due to different healthcare systems, treatment patterns, competitive dynamics
• VP-315 Clinical Development Risk: Phase 3 success uncertain despite FDA positive feedback; BCC market highly competitive with established treatments
• Partnership Dependency: Majority of near-term revenue dependent on Torii performance; Torii commercial challenges would impact Verrica revenue growth
• Competitive Threats: Large pharma entry into molluscum/warts space possible; BCC treatment competition intensifies; could erode YCANTH market share
• Small-Cap Volatility: Typical small-cap biotech volatility; binary risk profile (approval/failure); institutional ownership could create liquidity issues

Analyst Price Target Range

• Conservative Target: $8-12 per share (base case: approved product + Phase 3 program)
• Bull Case Target: $15-20+ per share (US approval + common warts expansion + VP-315 Phase 3 success)
• Bear Case Target: $3-5 per share (regulatory setback or partnership termination)
• Typical Biotech Comparison: Commercial-stage biotech with FDA-approved product, Phase 3 program, and partnership revenue typically trades 8-15x revenue or 20-40x EBITDA

⚠️ Comprehensive Risk Assessment